← Every applicant

Mylan FDA Approvals

30 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.

Newest first

A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.

Product
SUGAMMADEX SODIUMNew drugJul 28, 2026SOLUTION, INTRAVENOUS
FERRIC CARBOXYMALTOSENew drugJun 25, 2026SOLUTION, INTRAVENOUS
FERRIC CARBOXYMALTOSENew drugJun 25, 2026SOLUTION, INTRAVENOUS
APREPITANTNew drugMar 5, 2026EMULSION, INTRAVENOUS
MACITENTANNew drugDec 3, 2025TABLET, ORAL
LINAGLIPTINNew drugNov 3, 2025TABLET, ORAL
PACLITAXELNew drugAug 19, 2025POWDER, INTRAVENOUS
DARUNAVIRNew drugJul 22, 2025TABLET, ORAL
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATENew drugMay 20, 2025TABLET, ORAL
DABIGATRAN ETEXILATE MESYLATENew drugFeb 3, 2025CAPSULE, ORAL
ARIPIPRAZOLENew drugDec 3, 2024FOR SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATENew drugSep 5, 2024TABLET, ORAL
EPOPROSTENOL SODIUMNew drugJun 12, 2024INJECTABLE, INJECTION
DEXLANSOPRAZOLENew drugJan 19, 2024CAPSULE, DELAYED RELEASE, ORAL
LISDEXAMFETAMINE DIMESYLATENew drugAug 25, 2023CAPSULE, ORAL
DAPTOMYCINNew drugAug 7, 2023POWDER, INTRAVENOUS
SAXAGLIPTINNew drugJul 31, 2023TABLET, ORAL
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDENew drugJul 31, 2023TABLET, EXTENDED RELEASE, ORAL
REGADENOSONNew drugApr 4, 2023SOLUTION, INTRAVENOUS
SUCRALFATENew drugSep 12, 2022SUSPENSION, ORAL
LENALIDOMIDENew drugAug 30, 2022CAPSULE, ORAL
ERMEZANew drugApr 29, 2022SOLUTION, ORAL
BREYNANew drugMar 15, 2022AEROSOL, METERED, INHALATION
DAPSONENew drugFeb 4, 2022GEL, TOPICAL
CYCLOSPORINENew drugFeb 2, 2022EMULSION, OPHTHALMIC
POMALIDOMIDENew drugJan 26, 2022CAPSULE, ORAL
SUNITINIB MALATENew drugDec 6, 2021CAPSULE, ORAL
TICAGRELORNew drugJul 9, 2021TABLET, ORAL
LINACLOTIDENew drugFeb 9, 2021CAPSULE, ORAL
FINGOLIMOD HYDROCHLORIDENew drugJan 19, 2021CAPSULE, ORAL

Related datasets